550 related articles for article (PubMed ID: 29150198)
21. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
Solli KK; Latif ZE; Opheim A; Krajci P; Sharma-Haase K; Benth JŠ; Tanum L; Kunoe N
Addiction; 2018 Oct; 113(10):1840-1849. PubMed ID: 29806872
[TBL] [Abstract][Full Text] [Related]
22. Baseline- and treatment-associated pain in the X:BOT comparative effectiveness study of extended-release naltrexone versus buprenorphine-naloxone for OUD.
Wang AL; Shulman M; Choo TH; Pavlicova M; Langleben DD; Nunes EV; Rotrosen J
Addict Biol; 2022 Mar; 27(2):e13112. PubMed ID: 34877769
[TBL] [Abstract][Full Text] [Related]
23. Does XR injectable naltrexone prevent relapse as effectively as daily sublingual buprenorphine-naloxone?
Roe M; Wilson CG; Fusco CW; Hulkower S; Stigleman S
J Fam Pract; 2020 Dec; 69(10):E14-E15. PubMed ID: 33348352
[TBL] [Abstract][Full Text] [Related]
24. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
Lee JD; McDonald R; Grossman E; McNeely J; Laska E; Rotrosen J; Gourevitch MN
Addiction; 2015 Jun; 110(6):1008-14. PubMed ID: 25703440
[TBL] [Abstract][Full Text] [Related]
25. Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorder.
Paschen-Wolff M; Greenfield SF; Kathryn McHugh R; Burlew K; Pavlicova M; Choo TH; Barbosa-Leiker C; Ruglass LM; Mennenga S; Rotrosen J; Nunes EV; Campbell ANC
Am J Addict; 2023 Nov; 32(6):584-592. PubMed ID: 37583120
[TBL] [Abstract][Full Text] [Related]
26. Buprenorphine Naloxone and Extended Release Injectable Naltrexone for the Treatment of Opioid Use Disorder Among a Veteran Patient Sample: A Retrospective Chart Review.
Shirk SD; Ameral V; Kraus SW; Houchins J; Kelly M; Pugh K; Reilly E; Desai N
J Dual Diagn; 2021; 17(3):207-215. PubMed ID: 34176448
[TBL] [Abstract][Full Text] [Related]
27. Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study.
Latif ZE; Šaltyte Benth J; Solli KK; Opheim A; Kunoe N; Krajci P; Sharma-Haase K; Tanum L
JAMA Psychiatry; 2019 Feb; 76(2):127-134. PubMed ID: 30566177
[TBL] [Abstract][Full Text] [Related]
28. Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.
Mannelli P; Wu LT; Peindl KS; Swartz MS; Woody GE
Drug Alcohol Depend; 2014 May; 138():83-8. PubMed ID: 24602363
[TBL] [Abstract][Full Text] [Related]
29. Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.
Mooney LJ; Nielsen S; Saxon A; Hillhouse M; Thomas C; Hasson A; Stablein D; McCormack J; Lindblad R; Ling W
Contemp Clin Trials; 2013 Mar; 34(2):196-204. PubMed ID: 23159524
[TBL] [Abstract][Full Text] [Related]
30. Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network.
Montgomery L; Winhusen T; Scodes J; Pavlicova M; Twitty D; Campbell ANC; Wang AL; Nunes EV; Rotrosen J
J Subst Abuse Treat; 2021 Nov; 130():108489. PubMed ID: 34118716
[TBL] [Abstract][Full Text] [Related]
31. Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment.
Nunes EV; Scodes JM; Pavlicova M; Lee JD; Novo P; Campbell ANC; Rotrosen J
Am J Psychiatry; 2021 Jul; 178(7):660-671. PubMed ID: 34170188
[TBL] [Abstract][Full Text] [Related]
32. Optimizing opioid use disorder treatment with naltrexone or buprenorphine.
Rudolph KE; Díaz I; Luo SX; Rotrosen J; Nunes EV
Drug Alcohol Depend; 2021 Nov; 228():109031. PubMed ID: 34534863
[TBL] [Abstract][Full Text] [Related]
33. Risk of Relapse Among Opioid-Dependent Patients Treated With Extended-Release Naltrexone or Buprenorphine-Naloxone: A Randomized Clinical Trial.
Opheim A; Gaulen Z; Solli KK; Latif ZE; Fadnes LT; Benth JŠ; Kunøe N; Tanum L
Am J Addict; 2021 Sep; 30(5):453-460. PubMed ID: 34487395
[TBL] [Abstract][Full Text] [Related]
34. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.
Ling W; Hillhouse MP; Saxon AJ; Mooney LJ; Thomas CM; Ang A; Matthews AG; Hasson A; Annon J; Sparenborg S; Liu DS; McCormack J; Church S; Swafford W; Drexler K; Schuman C; Ross S; Wiest K; Korthuis PT; Lawson W; Brigham GS; Knox PC; Dawes M; Rotrosen J
Addiction; 2016 Aug; 111(8):1416-27. PubMed ID: 26948856
[TBL] [Abstract][Full Text] [Related]
35. Extended-release naltrexone for youth with opioid use disorder.
Mitchell SG; Monico LB; Gryczynski J; Fishman MJ; O'Grady KE; Schwartz RP
J Subst Abuse Treat; 2021 Nov; 130():108407. PubMed ID: 34118699
[TBL] [Abstract][Full Text] [Related]
36. Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial.
Marsden J; Kelleher M; Gilvarry E; Mitcheson L; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hardy W; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Vanderwaal R; Wareham A; Hughes D; Hoare Z
EClinicalMedicine; 2023 Dec; 66():102311. PubMed ID: 38045803
[TBL] [Abstract][Full Text] [Related]
37. Cost of pharmacotherapy for opioid use disorders following inpatient detoxification.
McCollister KE; Leff JA; Yang X; Lee JD; Nunes EV; Novo P; Rotrosen J; Schackman BR; Murphy SM
Am J Manag Care; 2018 Nov; 24(11):526-531. PubMed ID: 30452209
[TBL] [Abstract][Full Text] [Related]
38. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
[TBL] [Abstract][Full Text] [Related]
39. Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial.
Opheim A; Benth JŠ; Solli KK; Kloster PS; Fadnes LT; Kunøe N; Gaulen Z; Tanum L
Contemp Clin Trials; 2023 Dec; 135():107360. PubMed ID: 37865138
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
